• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RARE

    Ultragenyx Pharmaceutical Inc.

    Subscribe to $RARE
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: ultragenyx.com

    Recent Analyst Ratings for Ultragenyx Pharmaceutical Inc.

    DatePrice TargetRatingAnalyst
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    4/22/2024$77.00Outperform
    RBC Capital Mkts
    12/8/2023$72.00Overweight
    Wells Fargo
    6/14/2023$96.00Outperform
    Credit Suisse
    6/6/2023$60.00 → $80.00In-line → Outperform
    Evercore ISI
    4/26/2023$114.00Overweight
    Cantor Fitzgerald
    1/18/2023$90.00Buy
    Canaccord Genuity
    12/30/2022$82.00Buy
    H.C. Wainwright
    11/3/2022$50.00Neutral → Outperform
    Robert W. Baird
    10/13/2022$50.00Neutral → Buy
    Guggenheim
    See more ratings

    Ultragenyx Pharmaceutical Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

      NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed t

      5/7/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 36,831 restricted stock units of the company's common stock to 21 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

      4/22/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company's common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

      3/19/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Participate at Investor Conferences in March

      NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences. 45th Annual Cowen Healthcare Conference (Boston, MA) Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings. Barclays 27th Annual Global Healthcare Conference (Miami, FL) Tuesday, March 11, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings. Leerink Partners Global Biopharma Conference

      2/24/25 4:30:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the company's common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4

      2/19/25 4:30:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

      NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA). The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of August 18, 2025. The FDA also informed the company that they are not currently planning to hold an advisory committee meeting to discuss this application. "Acceptance of the UX111 BLA brings us closer to being able to provi

      2/18/25 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

      2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. "We have created a ne

      2/13/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

      NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 13, 2025, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx

      2/6/25 4:30:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/5/25 7:18:48 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/10/25 12:53:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:19:57 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP and Chief Legal Officer Parschauer Karah Herdman was granted 18,443 shares and sold $540,817 worth of shares (12,846 units at $42.10), increasing direct ownership by 8% to 75,287 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:18:24 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP and Chief Medical Officer Crombez Eric was granted 31,784 shares and sold $376,584 worth of shares (8,945 units at $42.10), increasing direct ownership by 49% to 71,922 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:16:48 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Pinion John Richard was granted 32,937 shares, sold $607,882 worth of shares (14,439 units at $42.10) and covered exercise/tax liability with 31 shares, increasing direct ownership by 21% to 108,428 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:12:26 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Kakkis Emil D was granted 150,560 shares and sold $4,153,571 worth of shares (98,434 units at $42.20), increasing direct ownership by 14% to 641,731 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:10:16 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Harris Erik was granted 35,256 shares and sold $635,836 worth of shares (15,103 units at $42.10), increasing direct ownership by 31% to 87,855 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:06:23 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Huang Dennis Karl was granted 32,937 shares and covered exercise/tax liability with 1,348 shares, increasing direct ownership by 38% to 114,591 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:02:17 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Accounting Officer Huizenga Theodore Alan was granted 9,392 shares, sold $40,711 worth of shares (967 units at $42.10) and covered exercise/tax liability with 141 shares, increasing direct ownership by 20% to 50,124 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:00:32 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. Financials

    Live finance-specific insights

    See more
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

      2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. "We have created a ne

      2/13/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

      NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 13, 2025, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx

      2/6/25 4:30:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

      Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa) NOVATO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious r

      11/5/24 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

      NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 5, 2024, to discuss its financial results and corporate update for the quarter ending September 30, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharma

      10/29/24 4:05:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

      NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, August 1, 2024, to discuss its financial results and corporate update for the quarter ending June 30, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmace

      7/25/24 4:05:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

      Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m. ET NOVATO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced positive topline results from the Phase 3 GlucoGene study (NCT05139316) evaluating DTX401, an investigational gene therapy for the treatment of patients aged eight years and older with glycogen storage disease type Ia (GSDIa). The study achieved its primary endpoint, demonstrating that treatment with DTX401 resulted in a statistically significant and clinically meaningful

      5/30/24 4:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

      First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million Presented positive interim Phase 1/2 data from GTX-102 Angelman syndrome study demonstrating that Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains consistent with or exceeding Dose-escalation Cohort data at Day 170 NOVATO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the d

      5/2/24 4:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

      NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link) and you will be provided

      4/25/24 4:30:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

      NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,

      7/12/23 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

      NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx's chief medical officer for gene therapy and inborn errors of metabolism. "Eric has extensive expertise in the development and execution of clinical development programs for rare genetic disorders and has been a driving force for our entire gene therapy pipeline," said Emil D. Kakkis, M.D., Ph.D., chief executive of

      3/14/23 8:30:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

      NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. "Dr. Ray brings to our Board of Directors decades of global experience as a physician researcher, biopharmaceutical executive, and champion for patient access to innovative treatments," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "His expertise

      4/22/22 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman

      Accomplished biotechnology executive brings over 40 years of commercial and leadership experience across multinational pharmaceutical and biotechnology companies to ShouTi ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the company's board of directors. "It is a true privilege to welcome Dan to ShouTi as Chairman of our board," said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi. "As an industry veteran with an outstanding track record in guiding companies across all stages of development an

      1/20/22 8:00:00 AM ET
      $NUVB
      $RARE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

      Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

      1/10/22 8:00:00 AM ET
      $RARE
      $TXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

      NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut

      6/30/21 8:30:00 AM ET
      $BGNE
      $LEGN
      $MTEM
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      11/14/24 6:42:29 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 10:03:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 7:46:34 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ultragenyx Pharmaceutical Inc.

      SC 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/13/24 3:41:49 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/8/24 10:18:47 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      1/29/24 3:26:27 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      9/11/23 1:33:44 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/23 12:38:10 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ultragenyx Pharmaceutical Inc.

      SC 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/23 10:10:46 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ultragenyx Pharmaceutical Inc.

      SC 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/6/23 2:58:20 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. SEC Filings

    See more
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      5/6/25 4:10:49 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.

      DEFA14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:01:02 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ultragenyx Pharmaceutical Inc.

      DEF 14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:00:35 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Ultragenyx Pharmaceutical Inc.

      144 - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/28/25 4:11:20 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Ultragenyx Pharmaceutical Inc.

      10-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      2/19/25 4:58:50 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      2/13/25 4:04:18 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ultragenyx Pharmaceutical Inc.

      SCHEDULE 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/12/25 11:42:47 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ultragenyx Pharmaceutical Inc.

      SCHEDULE 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/10/25 10:25:37 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      1/13/25 8:30:33 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Ultragenyx Pharmaceutical Inc.

      144 - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      12/30/24 4:32:25 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ultragenyx Pharmaceutical Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ultragenyx Pharma upgraded by Goldman with a new price target

      Goldman upgraded Ultragenyx Pharma from Neutral to Buy and set a new price target of $67.00 from $56.00 previously

      6/6/24 7:19:22 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ultragenyx Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ultragenyx Pharma with a rating of Outperform and set a new price target of $77.00

      4/22/24 7:43:41 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

      Wells Fargo initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $72.00

      12/8/23 7:56:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on Ultragenyx Pharma with a new price target

      Credit Suisse resumed coverage of Ultragenyx Pharma with a rating of Outperform and set a new price target of $96.00

      6/14/23 7:47:32 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharma upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Ultragenyx Pharma from In-line to Outperform and set a new price target of $80.00 from $60.00 previously

      6/6/23 7:51:41 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Ultragenyx Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $114.00

      4/26/23 7:37:50 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Ultragenyx Pharma with a new price target

      Canaccord Genuity resumed coverage of Ultragenyx Pharma with a rating of Buy and set a new price target of $90.00

      1/18/23 7:57:24 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Ultragenyx Pharma with a new price target

      H.C. Wainwright resumed coverage of Ultragenyx Pharma with a rating of Buy and set a new price target of $82.00

      12/30/22 7:37:30 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharma upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Ultragenyx Pharma from Neutral to Outperform and set a new price target of $50.00

      11/3/22 7:32:34 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Pharma upgraded by Guggenheim with a new price target

      Guggenheim upgraded Ultragenyx Pharma from Neutral to Buy and set a new price target of $50.00

      10/13/22 7:57:30 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care